Sotrovimab

Phase 3Monoclonal antibody

Sotrovimab is a monoclonal antibody that works as a Spike Glycoprotein Inhibitor.[2] It is being investigated across 2 indications, with its most advanced program in Phase 3.[1]

Sotrovimab is one of 65 small molecule programs targeting Severe Acute Respiratory Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Acute Respiratory SyndromeActive, not recruiting

COVID-19Active, not recruiting

Severe Acute Respiratory SyndromePhase 2

Active, not recruiting

COVID-19Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Sotrovimab

VVir Biotechnology, Inc.

Phase 3

15 2

COVID-19 Vaccine

Moderna

Preclinical

27 3

Stivarga

Bayer

Preclinical

1 4

Aimovig

Amgen

Preclinical

1 5

Aldactone

Pfizer

Preclinical

1 6

Nexavar

Bayer

Preclinical

1 7

Activella

Eli Lilly

Preclinical

—8

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 9

Benadryl

PParkedale

Preclinical

1 10

SARS-COV-2 VACCINE

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

COVID-19

NCT05041907

Q2 2036

Phase 3Recruiting

COVID-19

NCT04381936

Clinical

Trials by Indication[1]

COVID-1915 trials

UPMC OPTIMISE-C19 Trial, a COVID-19 Study

Terminated·EErin McCreary·Phase 4·NCT04790786·4,571 enrolled

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

No longer available·VVir Biotechnology, Inc.··NCT05235347

Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19

Completed· GSK logo

GSK·Phase 4·NCT05305651·217 enrolled

Show 12 more trials

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

Terminated·VVir Biotechnology, Inc.·Phase 3·NCT04913675·1,065 enrolled

COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2

Completed·UUniversity of Milano Bicocca··NCT05268601·251 enrolled

A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals

Completed·—·Phase 2·NCT05210101·93 enrolled

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

Completed·—·Phase 2/3·NCT04870333·2,240 enrolled

Non-inferiority Trial on Monoclonal Antibodies in COVID-19

Terminated·AAzienda Ospedaliera Universitaria Integrata Verona·Phase 3·NCT05205759·319 enrolled

Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study

Terminated·FFred Hutchinson Cancer Center·Phase 1·NCT05135650·20 enrolled

Randomised Evaluation of COVID-19 Therapy

Recruiting·UUniversity of Oxford·Phase 3·NCT04381936·70,000 enrolled

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

Recruiting·UUniversity of Oxford·Phase 2·NCT05041907·3,800 enrolled

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

Terminated· GSK logo

GSK·Phase 2·NCT05124210·8 enrolled

Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain

Unknown status·AAbu Dhabi Health Services Company··NCT05398718·20,000 enrolled

Non-inferiority Trial on Treatments in Early COVID-19

Completed·AAzienda Ospedaliera Universitaria Integrata Verona·Phase 3·NCT05321394·536 enrolled

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

Completed·VVir Biotechnology, Inc.·Phase 2·NCT04779879·354 enrolled

ART1 trial

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

Completed·VVir Biotechnology, Inc.·Phase 1·NCT04988152·48 enrolled

Cohort Study1 trial

TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2

Completed·—··NCT05195060·1,178 enrolled

Adult1 trial

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

Terminated·VVir Biotechnology, Inc.·Phase 1·NCT05280717·316 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for Sotrovimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sotrovimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sotrovimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vir Biotechnology, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Spike Glycoprotein Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: VVir Biotechnology, Inc.

Sotrovimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2036

Trials by Indication[1]

COVID-1915 trials

ART1 trial

Cohort Study1 trial

Adult1 trial

References

Drug Info

Quick Facts

Related News